Oura unveiled its fifth-generation smart ring on May 28, 2026, a device the company says is 40% smaller than its predecessor while adding blood pressure signal tracking, GLP-1 medication insights, and — for the first time — direct access to licensed physicians through an in-app AI partnership with Counsel Health. The launch marks Oura’s clearest pivot yet from a sleep-and-fitness tracker toward something closer to a continuous, AI-mediated health record that users carry on their finger.
A Smaller Ring, A Bigger Ambition
Oura Ring 5 started shipping June 4, 2026, priced at $399 for Silver and Black finishes and $499 for Gold, Stealth, Brushed Silver, and Deep Rose. Beyond the size reduction, the headline features are clinical in nature: a “Health Radar” tool that monitors nighttime breathing and flags blood pressure-related signal changes that may warrant a doctor’s visit, plus GLP-1 Insights designed for the growing population of users on weight-loss drugs like Ozempic and Wegovy who want to track how the medication is affecting their sleep, heart rate, and recovery over time. CEO Tom Hale described the launch as “a big step toward our vision of giving everybody a voice,” framing the ring less as a fitness gadget and more as a personal health data platform.
Oura Advisor Gets Smarter — and More Specialized
The ring’s hardware upgrades arrive alongside a maturing AI layer. Oura Advisor, the company’s large language model-powered in-app assistant first launched in 2025, lets users ask natural-language questions about their own Sleep, Activity, Readiness, and Resilience data instead of parsing raw charts. In Oura Labs testing ahead of wider rollout, the company logged over 1 million messages sent to Advisor, with 60% of testers using it weekly and 83% rating its answers reliable; 60% said it clarified metrics they had previously misunderstood. In April 2026, Oura layered in a proprietary women’s health model, reviewed by board-certified clinicians, that can field questions spanning the full reproductive health arc from early menstrual cycles through menopause — a notable expansion given how much of the wearable health market has historically been built around default male physiology.
Handing Off to a Real Doctor
Perhaps the more consequential shift is Oura’s new partnership with Counsel Health, an on-demand care platform that pairs medical AI with licensed physicians. Starting in June 2026, eligible Oura members in 43 states can ask health questions inside the Oura app, get AI-assisted medical guidance, and connect with a licensed provider within minutes if the situation calls for it. That closes a gap that has dogged consumer wearables for years: devices could flag an anomaly, but users were left to decide for themselves whether an elevated resting heart rate or disrupted sleep pattern was worth a trip to urgent care.
The Skeptic’s Case
Not everyone is convinced wearable-triggered medical guidance is ready for prime time. Clinicians have long raised concerns about consumer devices generating false positives — flagging normal physiological variation as a health risk and driving anxious users into unnecessary doctor visits or, conversely, giving false reassurance that delays needed care. Blood pressure signal detection via a ring, in particular, is a far cry from a validated cuff-based reading, and Oura has been careful to frame Health Radar as a signal for “lifestyle adjustments or medical follow-up” rather than a diagnostic tool. Critics also note that stacking an AI chat layer on top of unvalidated biometric inferences risks compounding uncertainty with false confidence, especially for users who may trust an AI’s phrasing more than the underlying data warrants.
The Business Case Driving the Push
Commercially, the stakes are enormous. Oura announced an $11 billion valuation in October 2025 alongside a $900 million Series E round, and Hale said in November 2025 the company could approach $2 billion in 2026 sales. That kind of valuation increasingly rests on Oura proving it’s more than a sleep tracker competing with Whoop and Apple Watch — it needs to look, to investors and eventually to insurers, like a legitimate node in the healthcare system. Partnering with a clinical AI-and-physician service like Counsel Health is as much a credibility play as a product feature, aimed at persuading doctors who have historically dismissed wearable data as noise.
What’s Next for Wearable Medicine
The real test will come over the next year as Health Radar and the Counsel Health partnership scale beyond early access and regulators and physicians get more visibility into how often the AI’s flags prove clinically meaningful versus noisy. If Oura can show its blood pressure signals and AI triage reliably catch real problems without flooding primary care with false alarms, it could accelerate a broader shift of wearables from lifestyle gadgets into recognized tools for preventive medicine — a transition Hale and Oura are explicitly betting their next funding round and valuation on.
Photo: fancycrave1 / PIXABAY via Pixabay
